SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin settles patent suit with Medicis, signs R&D pact

26 Jul 2011 Evaluate

Drug maker Lupin had settled all patent litigation over Solodyn tablets with Medicis Pharmaceutical Corp and signed a pact with the US-based firm for development of multiple therapeutic compounds. The pact would entail the Indian company receiving up to $38 million (over Rs 165 crore).

After the settlement agreement for the anti-biotic used for treating acne, Lupin is entitled to sell its generic versions of Solodyn in 45 mg, 90 mg, and 135 mg strengths under a licence from Medicis commencing November 2011, or earlier under certain conditions. The settlement also entitles Lupin to sell its generic versions of Solodyn in 65 mg and 115 mg strengths under a license from Medicis effective in February 2018. Further, Lupin can sell its generic versions of Solodyn in 55 mg, 80 mg and 105 mg strengths under a license from Medicis effective in February 2019, or earlier depending on certain conditions.

In another development, the company had also signed a research and development agreement with Medicis Pharmaceutical Corp. Under the terms of the agreement, Lupin will receive a $20 million (nearly Rs 90 crore) upfront payment from Medicis. The company will be primarily responsible for formulating certain novel therapeutic products for Medicis, utilising several of Lupin's formulation technologies. On the other hand, Medicis will have global exclusive rights (excluding India) for the products developed under the agreement. Lupin will be eligible for future research, development, regulatory and other milestones [payments] of up to $38 million, as well as a single digit royalty on sales by Medicis.crackcrack

Lupin Share Price

2264.20 18.55 (0.83%)
12-May-2026 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1857.00
Dr. Reddys Lab 1278.60
Cipla 1296.00
Zydus Lifesciences 937.00
Lupin 2264.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×